

DISEASE, DIAGNOSES, AND DOLLARS

**DISEASE,
DIAGNOSES,
and DOLLARS**

Facing the Ever-Expanding Market for Medical Care

Robert M. Kaplan



COPERNICUS BOOKS

An Imprint of Springer Science+Business Media

© 2009 Springer Science+Business Media, LLC

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher.

Published in the United States by Copernicus Books,
an imprint of Springer Science+Business Media.

Copernicus Books
Springer Science+Business Media
233 Spring Street
New York, NY 10013
www.springer.com

Library of Congress Control Number:
2008935538

Manufactured in the United States of America.
Printed on acid-free paper.

ISBN 978-0-387-74044-7

e-ISBN 978-0-387-74045-4

Preface

Good health is our most precious asset. Without health, life becomes much more challenging. Because health is so central in our lives, we invest trillions of dollars to achieve more wellness or to remedy diseases. A vast healthcare establishment is ready and willing to receive these investments. Some investments in healthcare result in healthier and happier citizens. Other investments have little effect on health, are wasteful, and even harmful.

It is widely acknowledged that there is a serious crisis in American healthcare. There is no real healthcare system in the USA. Instead, we have a patchwork of competing systems. Medicare covers the elderly and people with some defined problems, such as kidney failure. Medicaid covers the blind, the disabled, and families with dependent children. Most people have private insurance that is paid for by their employers. The public systems are in financial trouble, and an increasing number of employers claim that they are no longer able to pay for insurance. The number of uninsured or underinsured people in the USA has soared to well over 45 million.

Proposals for national health insurance abound. However, virtually all of the proposals focus on providing coverage for all people. Although universal healthcare is an attractive goal, there is another problem. We have been persuaded to want more healthcare than we need. A *New York Times* article by columnist Gena Kolata [1] described patients lining up for all of the care that Medicare will cover. The article describes patients in a Florida clinic seeking every service that the Medicare program will pay for. They ask for the latest diagnostic tests, and they want the latest medicines that they have learned about by watching advertisements on television. The Medicare system, in some ways, encourages this. If a service is covered, the provider only needs to send in the bill and he will be paid. Is all of this medical care necessary?

This book is about some disquieting conflicts between consumers and their healthcare providers. Our healthcare system is big and complicated: it is the largest sector in the biggest economy in the history of the world. But, unlike other industries, healthcare has not been held accountable for what it produces. We know, for example, that the USA spends significantly more per capita on healthcare than any other country. Yet, we rank last among comparison countries in the Organization for Economic Cooperation and Development

on the major health indicators. We also know that there are substantial regional differences in healthcare expenditures within the USA. Even when we adjust for a variety of variables, such as age distribution, poverty, education, or minority status, regions that spend more do not have better outcomes, and some evidence suggests that quality of care is lower in the regions that spend more, not less, on healthcare.

Our problem is not that providers charge too much, it is that they do too much. We assume that the high costs of healthcare reflect the expense of services and medications. *Disease, Diagnosis, and Dollars* calls this assumption into question. Drug prices in the USA are not significantly higher in comparison with that in other developed countries, because few patients actually pay the listed retail price. Total costs are a function of two factors: unit price and volume. Volume, not unit cost, may be driving our healthcare crisis. The following chapters suggest that mass markets have been created for services that may offer little or no benefit to patients. Many of these markets are for preventive medicine. These include cancer-screening tests, and medications to control blood pressure, cholesterol, and glucose. The attractiveness of preventive medicine is that it can make well people a market for expensive pharmaceutical products and tests.

These mass markets have been nurtured with the support of respected panels of experts who have created guidelines for new tests to diagnose illness and new drugs to treat disease. New revisions of these guidelines are unlikely to benefit most consumers of healthcare. Still, these guidelines are used to set standards for the practice of medicine, and quality of care is often defined as adherence to the standards. Once the guidelines are set, doctors follow them. We have been intentionally led to believe tests and medicines will offer greater benefits than evidence supports. The result: uncontrollable costs and minimal benefits.

There are consequences to the overuse of medications and tests. Although most screening tests and modern medicines used in prevention are safe for individuals, their use runs up the costs of healthcare. High costs result in higher insurance premiums for all of us. As more employers drop health insurance for their employees when costs accelerate, the expanded use of ineffective preventive medicine may have the unintended consequence of increasing the number of uninsured patients, potentially damaging the health of others in the community.

The concluding chapters offer suggestions for policy makers and for patients. Methods for systematically evaluating the cost-effectiveness of new guidelines are discussed. The final chapter provides practical suggestions to enable patients to share in decisions about treatments or tests that can have uncertain benefits.

Many colleagues have contributed to the development of this manuscript. I started thinking about these problems 10 years ago during a sabbatical year at the Dartmouth Medical School. That year I got to know Elliott Fisher, Gil Welch, Lisa Schwartz, and Jack Wennberg. The Dartmouth experience shaped my thinking about overuse in medical care. The ideas for the book have been

shaped by a dozen years of experience as a faculty member for the American Health Association US Seminar on the Epidemiology and Prevention of Cardiovascular Disease. The core of the book has been adapted from the lectures I offered at the Lake Tahoe seminar. While a professor at the University of California, San Diego School of Medicine, close colleagues including Rick Kronick, Robert Langer, and Ted Ganiats discussed these ideas with me on many occasions. I am particularly indebted to Mike Criqui, a noted physician epidemiologist who, over the course of 25 years, systematically taught me the basics of epidemiology and helped sharpen my thinking. Mike may not agree with all of the ideas in this book, but I hope he will see that he inspired some of the critical reflection. At UCLA, I benefited from feedback from Gerald Kominski, Tom Rice, Bill Cononar, Dominick Frosch, and several others. Readings of early chapters by Andrea Grefe and Margaret Gaston guided the direction and the prose. I am most sincerely appreciative for the detailed feedback I received from Paul Farrell from Springer and Copernicus Press. Paul critiqued every page, challenged the thinking and the writing, and made the manuscript better in countless ways. My senior editor Bill Tucker has also been exceptionally helpful. Finally, I am most indebted to the Rockefeller Foundation who provided a quiet study in Bellagio overlooking Lake Como Italy, where the manuscript was finally completed. The fellow resident scholars at Bellagio also provided very valuable feedback.

I expect that many intelligent and well-informed readers will disagree with some of the basic premises in these chapters: the book was intended to be provocative. However, the text is built upon data from contemporary, peer-reviewed literatures in medicine and health services research. I hope the book stimulates debate, fosters new research, and makes us wiser consumers of healthcare.

Robert M. Kaplan
rmkaplan@ucla.edu
Los Angeles, California
June 2007

Reference

1. Kolata G. Patients in Florida lining up for all that Medicare covers. *New York Times*, 2003.

Contents

1	Disease, Outcomes, and Money	1
	Buying Health, Buying Healthcare	2
	Is More Better?	3
	What Is Wrong?	4
	References	5
2	The Disease-Reservoir Hypothesis	7
	What Is Disease?	9
	Testing the Disease-Reservoir Hypothesis	11
	The Geographic Distribution of Health Services	13
	A Case Study	14
	Studies of Regional Variation in Service and Spending	15
	Variation and Cost	17
	References	18
3	Mental Models of Health and Healthcare	21
	The Human Body: Component Parts or Systems?	23
	Chronic versus Acute Disease	24
	Common-Sense Models	26
	Statistics and Mental Models	27
	Mental Models and the People We Most Trust	31
	References	34
4	What Is Disease and When Does It Begin?	35
	Common Perceptions of Chronic Disease	35
	More Is More, But Is More Better?	36
	When Does Chronic Disease Begin?	38
	What are the Implications of These Findings?	40
	Primary versus Secondary Prevention	44
	References	44

5 Screening for Cancer 47

Public Enthusiasm for Screening 48

Questions about the Value of Screening on Public Health 49

Biases in the Interpretation of Screening Studies 50

 Lead-Time Bias 50

 Length Bias 51

Does Screening Find the Wrong Cases? 53

What do RCTs on Screening Tell Us? 55

Evidence-Based Medicine Approach 60

Interpretation of Cancer-Screening Evidence by Peer Panels 61

The Mammography Paradox 63

How Many Screening Tests are Needed to Prevent a Death? 66

Variations in Screening Rates and Impacts on Healthcare Costs 67

Conclusions 69

References 70

6 Deciding When Blood Pressure Is Too High 73

Definition of Health Outcomes 75

What Is Blood Pressure? 77

Does Blood Pressure Treatment Save Lives? 78

Review of Controversies 79

 JNC-7 81

Justification for Lowering the Threshold 82

Likelihood of Benefit–Chances of Side Effects 86

How Many People Will be Affected by the New Guidelines? 88

Paradoxical Treatment Effects 90

Conclusions 91

References 92

7 The Cholesterol Cutoff 95

Cholesterol Screening 100

 ATP III 102

Concerns and Conflicts of Interest 103

 How Many People are Affected by the Changing Definitions? 103

 How Many Will Progress to CVD? 106

Conclusions 108

References 108

8 Diabetes, Obesity, and the Metabolic Syndrome 111

Pathophysiology 112

The Changing Definition of Diabetes and Impaired
Fasting Glucose 114

IFG and Its Consequences 115

Obesity and Overweight 118

The Metabolic Syndrome 125

Conclusions 128

References 129

9 Cost-Effectiveness and Opportunity Costs 131

Uninsured Americans: A Result of Too Many Tests? 134

The Costs of Care 136

Outcomes in Chronic Illness 136

Mortality 137

Health-Related Quality of Life 138

Opportunity Costs 139

Primary-Prevention Approaches 141

Physical Activity 142

League Table 144

Summary 145

References 146

10 Shared Medical Decision-Making 149

Uncertainty in Medicine 149

Shared Decision-Making 150

Why Shared Decisions are Necessary 152

The Reliability and Consistency of Clinical Decisions 154

Do Patients Want to Participate in Decision-Making? 155

What Is the Patient’s Role in Making Decisions? 155

Shared Decision-Making and the Overuse of Medical Services 157

Consumer-Driven Health Plans 162

Conclusions 163

References 163

11 Putting the Pieces Together 167

Costs are Out of Control 167

The Proliferation of Services 168

Changes in Communications with Patients 170

We Need to Re-examine the Process of Developing
Practice Guidelines 173

References 178

Index 179

List of Figures

2.1	Percent of disk bulges discovered by Magnetic Resonance Imaging (MRI) in volunteers without back pain	10
2.2	Mammography and breast carcinoma in situ (CIS) by age	13
2.3	Differences in Medicare expenditures.	15
2.4	Inpatient and Part B Medicare spending.	16
2.5	Relationship between hospital beds and hospitalization rates	18
3.1	Total mortality in the Aspirin component of the Physicians' Health Study	28
3.2	Absolute change in death in the Aspirin component of the Physicians' Health Study	29
3.3	CHD and non-CHD deaths in the Helsinki Heart Study	30
3.4	Effects of celebrity endorsements for cancer screening	33
4.1	Incidence of melanoma and death from melanoma between 1986 and 2001	36
4.2	Skin biopsies and melanoma 100,000/population in 1986, 2001, and the interval 1987–2000	37
4.3	Prostate cancer among 525 Detroit men who died of violence or in accidents	37
4.4	Atherosclerosis timeline	38
4.5	Abdominal aortic lesions	39
4.6	Relationship between angiography and procedures in Medicare claims.....	41
4.7	Cumulative rate of angiography in the Unites States and Canada by weeks following Myocardial Infarction	42
4.8	Cumulative rate of PT and Coronary Artery Bypass Graft (CABG) surgery in the Unites States and Canada by weeks following Myocardial Infarction	42
4.9	Cumulative mortality in the Unites States and Canada by weeks following Myocardial Infarction	43
5.1	Breast cancer diagnoses and deaths in France	50
5.2	Example of lead time bias	51
5.3	Length Bias	52
5.4	Length Bias with newer test.....	53

5.5 Detection of rapidly progressing and slowing progressing cancers 54

5.6 Screening leads to more screening 54

5.7 Number of colon or rectal cancer deaths in the Minnesota
colon-cancer-screening trail 60

5.8 Number of deaths from all causes in the Minnesota
colon-cancer-screening trail 61

5.9 Relative risk and confidence intervals for mammography RCTs..... 63

5.10 Overall cumulative breast cancer mortality rates. 64

5.11 Expected and observed cumulative incidence of invasive..... 65

6.1 Population systolic pressure and stroke in the Whitehall Study 74

6.2 Prevalence in high blood pressure. 78

6.3 Age-adjusted prevalence. 81

6.4 Blood pressure and the risk of stroke. 83

6.5 Data from the Prospective Studies Collaboration (Fig. 6.4)
with linear units 84

6.6 Relationship between the benefits of treatment and the risks
of the illness 87

6.7 Distribution of systolic blood pressure from the. 89

7.1 Relationship between median total cholesterol. 96

7.2 CHD deaths by total cholesterol 97

7.3 Percentage of participants who had died. 98

7.4 Percentage of participants not dying of. 99

7.5 Distribution of LDL cholesterol for all participants. 104

7.6 Relationship between LDL and coronary. 104

7.7 Relationship between LDL and coronary. 105

7.8 Six-year CHD mortality by total serum. 105

7.9 Change in absolute risk reduction for three. 107

8.1 Proportion of the population age 20 years and older. 112

8.2 Relationship between BMI category. 119

8.3 Increase in the number of people identified 119

8.4 Barry bonds is obese. 120

8.5 Time trends in the prevalence of overweight. 122

8.6 The relationship between BMI and mortality. 122

8.7 The risk of death between 1995 and 2005 for AARP. 123

8.8 Scores on a general quality of life measure. 124

8.9 Man with metabolic syndrome 125

8.10 Prevalence of metabolic syndrome in men. 127

9.1 Life expectancy in selected developed countries 2005 132

9.2 The relationship between Medicare. 133

9.3 Percentage of uninsured workers. 136

9.4 Cost/QALY of lifestyle and metformin. 141

9.5 Graphic League Table analysis of Cost/QALY for
several programs 144

10.1	Advertisement for LIPITOR aimed at direct marketing to patients	157
10.2	Cumulative probability of surgery.....	159
10.3	The percentage of women... ..	160
10.4	Percentage of men choosing PSA... ..	161
11.1	Money spent by Political Action Committees on health... ..	175

List of Tables

- 2.1 What percentage of people has cancer? 11
- 2.2 Prevalence of Ductile Carcinoma in Situ (DCIS) by number
of slides per women in four different studies 12
- 3.1 Calculation of relative risk reduction 27
- 3.2 Calculation of absolute risk reduction 27
- 3.3 Absolute Risk Reduction (ARR) 28
- 3.4 Calculation of relative risk reduction and absolute risk reduction
in the Helsinki Heart Study 29
- 5.1 Summary of clinical trials with reports of total mortality—original,
permission not needed 56
- 5.2 Disease-specific and all-causes mortality and AARs for RCTs of
screening 58
- 5.3 Summary of recommendations for PSA screening..... 62
- 5.4 Summary of cancer-screening tests 68
- 6.1 Changing disease thresholds 76
- 6.2 How many new cases of disease were created by changes in
diagnostic thresholds? 76
- 6.3 Characteristics of participants in selected studies of hypertension
treatment 85
- 7.1 Meta-analyses summarizing the effects of cholesterol. 101
- 7.2 Entry criteria in trials used as the basis. 106
- 8.1 Percentage of participants with complications in kidney 117
- 8.2 Definitions for metabolic syndrome 126
- 8.3 Summary of concerns regarding the metabolic. 128